A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+breast cancers: a 2538-case multicenter study on consecutive surgical specimens
机构：[1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.四川大学华西医院[2]Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.四川大学华西医院[3]Department of Epidemiology and Biostatistics, West China School of Public Health, Sichuan University, Chengdu, Sichuan Province, China.[4]Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’ s Hospital, Chengdu, Sichuan Province, China.四川省人民医院[5]Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai, China.[6]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.河北医科大学第四医院[7]Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.[8]Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.[9]Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.广东省人民医院[10]Department of Pathology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.浙江大学医学院附属第一医院[11]Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.[12]Department of Pathology, Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi Province, China.[13]Department of Pathology, Xijing Hospital, the Air Force Military Medical University, Xi'an, Shanxi Province, China.[14]Department of Pathology, Shanxi Cancer Hospital, Taiyuan, Shanxi Province, China.[15]Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Objective: To investigate the proportion of HER2 gene amplifications and the association between the HER2-IHC-staining pattern and gene status in IHC-2+ breast cancers according to 2013 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Methods: We retrospectively analyzed and re-evaluated the IHC-staining pattern of 2538 IHC-2+ surgical specimens of breast cancer from November 2014 to October 2015 in 12 institutions. All cases used for building a prediction model of HER2 gene amplification according to the IHC-staining pattern and were randomly divided into a training set (n = 1914) or validation set (n = 624). Results: The overall HER2 fluorescence in situ hybridization (FISH) amplification, non-amplification and equivocation rates in HER2 IHC-2+ cases were 17.8%, 76.2% and 6.0%, respectively. In the training set, cases that had <= 10% of cells with intense, complete and circumferential membrane staining or had > 85% of cells with complete membrane staining of any staining intensity tended to be HER2 gene amplified (77.0% and 60.5%, respectively). And cases with weak and incomplete membrane staining had the lowest amplification rate of 6.1%. The prediction model was constructed based on IHC-staining pattern in the training set and validated using a validation set. The positive and negative prediction values were 51.6% and 79.2%, respectively, in the validation set. Moreover, the HER2 copy number per cell was much higher in cases with amplification-associated staining patterns (7.84 and 8.75) than in cases with non-amplification-associated staining patterns (2.97 to 4.41, P < 0.05). Conclusions: In HER2 IHC-2+ breast cancers, the staining pattern is associated with the HER2 gene status. This finding is compatible with recommendations of 2013 ASCO/CAP guidelines.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81702599]
第一作者机构：[1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.[2]Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
通讯作者：
通讯机构：[1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.[2]Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.[*1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China[*2]Department of Pathology and Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
推荐引用方式(GB/T 7714)：
Libo Yang,Zhang Zhang,Jiayuan Li,et al.A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+breast cancers: a 2538-case multicenter study on consecutive surgical specimens[J].JOURNAL OF CANCER.2018,9(13):2327-2333.doi:10.7150/jca.25586.
APA：
Libo Yang,Zhang Zhang,Jiayuan Li,Min Chen,Jieliang Yang...&Deyu Guo.(2018).A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+breast cancers: a 2538-case multicenter study on consecutive surgical specimens.JOURNAL OF CANCER,9,(13)
MLA：
Libo Yang,et al."A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+breast cancers: a 2538-case multicenter study on consecutive surgical specimens".JOURNAL OF CANCER 9..13(2018):2327-2333
